Evidence map›Paper›PMID 38958375›Full record

ArticleBioconjugate chemistry2024

Synthesis, Characterization, and Potential Usefulness in Liver Function Assessment of Novel Bile Acid Derivatives with Near-Infrared Fluorescence (NIRBAD).

Alvaro G Temprano, Beatriz Sanchez de Blas, Concepción Pérez-Melero, Ricardo Espinosa-Escudero, Oscar Briz, Paula Cinca-Fernando, Lucia Llera, Maria J Monte, Francisco A Bermejo-Gonzalez, Jose J G Marin and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioconjugate chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alvaro G TempranoExperimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, IBSAL, Salamanca 37007, Spain.
Beatriz Sanchez de BlasExperimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, IBSAL, Salamanca 37007, Spain.
Concepción Pérez-MeleroPharmaceutical Chemistry Laboratory, Pharmaceutical Sciences Department, University of Salamanca, IBSAL, Salamanca 37007, Spain.ORCID 0000-0002-6791-7927
Ricardo Espinosa-EscuderoExperimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, IBSAL, Salamanca 37007, Spain.
Oscar BrizExperimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, IBSAL, Salamanca 37007, Spain.
Paula Cinca-FernandoExperimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, IBSAL, Salamanca 37007, Spain.ORCID 0000-0003-4929-9595
Lucia LleraExperimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, IBSAL, Salamanca 37007, Spain.
Maria J MonteExperimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, IBSAL, Salamanca 37007, Spain.
Francisco A Bermejo-GonzalezOrganic Chemistry, School of Chemistry, University of Salamanca, Salamanca 37007, Spain.
Jose J G MarinExperimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, IBSAL, Salamanca 37007, Spain.ORCID 0000-0003-1186-6849
Marta R RomeroExperimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, IBSAL, Salamanca 37007, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Conventional serum markers often fail to accurately detect cholestasis accompanying many liver diseases. Although elevation in serum bile acid (BA) levels sensitively reflects impaired hepatobiliary function, other factors altering BA pool size and enterohepatic circulation can affect these levels. To develop fluorescent probes for extracorporeal noninvasive hepatobiliary function assessment by real-time monitoring methods, 1,3-dipolar cycloaddition reactions were used to conjugate near-infrared (NIR) fluorochromes with azide-functionalized BA derivatives (BAD). The resulting compounds (NIRBADs) were chromatographically (FC and PTLC) purified (>95%) and characterized by fluorimetry,

Indexed as

Bile Acids and SaltsFluorescent DyesLiverAnimalsCHO CellsCricetulusFluorescenceLiver Function TestsMaleRatsRats, Sprague-DawleySpectroscopy, Near-InfraredBile Acids and SaltsFluorescent Dyes

Identifiers

PMID38958375
PMCPMC11261600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.